文献速递甲状腺疾病

TERT启动子突变通过改变甲状腺乳头状癌中TERT mRNA剪接增加肿瘤侵袭性

TERT Promoter Mutations Increase Tumor Aggressiveness by Altering TERT mRNA Splicing in Papillary Thyroid Carcinoma.
PubMed 文献 · J Clin Endocrinol Metab · 2024-01-01

研究纳入2001年11月至2020年3月在长崎大学医院和隈医院手术的207例甲状腺乳头状癌(PTC),分析TERT启动子(TERT-p)突变状态与TERT剪接变异体(α缺失dA、β缺失dB)表达及临床病理特征的关系。TERT-p突变见于33例,174例突变阴性中24例有TERT表达。TERT-p突变阳性组+A+B/dB比值显著高于突变阴性/表达阳性组;+A+B表达与更高侵袭性相关,而dB表达拮抗该效应,体外实验提示dB有抑瘤作用。

要点

  • TERT-p突变见于33/207例PTC,突变阴性中24例有TERT表达。
  • TERT-p突变阳性组+A+B/dB比值显著高于突变阴性/表达阳性组。
  • +A+B表达与更高PTC侵袭性相关,dB表达拮抗此效应,体外实验提示dB抑瘤。

核心结论

  • TERT-p突变改变不同TERT剪接变异体的表达,进而与不同肿瘤侵袭性相关。

研究设计与样本

  • 研究纳入2001年11月至2020年3月在长崎大学医院和隈医院手术的207例PTC,分析TERT-p突变状态、TERT剪接变异体表达与临床病理特征的关系。

主要发现

  • TERT-p突变见于33例,174例突变阴性中24例有TERT表达。
  • TERT-p突变阳性组+A+B/dB比值显著高于突变阴性/表达阳性组。
  • +A+B表达与更高PTC侵袭性相关,而dB表达拮抗该效应。
  • 体外功能实验显示dB强烈抑制细胞生长、迁移和克隆形成,提示其抑瘤作用。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Telomerase reverse transcriptase promoter (TERT-p) mutations, which upregulate TERT expression, are strongly associated with tumor aggressiveness and worse prognosis in papillary thyroid carcinomas (PTCs). TERT expression is also observed in a proportion of PTCs without TERT-p mutations, but such tumors show less aggressiveness and better prognosis than TERT-p mutation-positive tumors. OBJECTIVE: TERT has multiple splicing variants whose relationships with the TERT-p status and clinicopathological characteristics remain poorly understood. We examined the relationship between the TERT-p mutational status, the TERT splicing pattern, and clinicopathological features. METHODS: We investigated the expression of 2 major variants, α deletion (dA) and β deletion (dB), in a series of 207 PTCs operated on between November 2001 and March 2020 in Nagasaki University Hospital and Kuma Hospital. RESULTS: The TERT-p mutations were found in 33 cases, and among 174 mutation-negative cases, 24 showed TERT expression. All cases were classified into 3 groups: the TERT-p mutation-negative/expression-negative group (mut-/exp-), the TERT-p mutation-negative/expression-positive group (mut-/exp+), and the TERT-p mutation-positive group (mut+/exp+). The +A+B/dB ratio in mut+/exp+ was significantly higher than that in mut-/exp+ PTCs. Analysis with clinicopathological data revealed that +A+B expression was associated with higher PTC aggressiveness, whereas dB expression counteracted this effect. Functional in vitro study demonstrated that dB strongly inhibited cell growth, migration, and clonogenicity, suggesting its tumor-suppressive role. CONCLUSION: These results provide evidence that the TERT-p mutations alter the expression of different TERT splice variants, which, in turn, associates with different tumor aggressiveness.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Sako A, Matsuse M, Saenko V, et al. TERT Promoter Mutations Increase Tumor Aggressiveness by Altering TERT mRNA Splicing in Papillary Thyroid Carcinoma. J Clin Endocrinol Metab. 2024. PMID: 38576411. doi:10.1210/clinem/dgae220

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。